Efficacy News and Research

RSS

Seven physicians receive ASTRO grants to advance radiation oncology research

The American Society for Radiation Oncology has selected seven leading physicians to receive a total of $675,000 in awards and grants to advance radiation oncology research. The ASTRO Junior Faculty Career Research Training Award, the ASTRO Residents/Fellows in Radiation Oncology Research Seed Grant and the ASTRO/Radiation Oncology Institute Comparative Effectiveness Research Award will fund studies in radiation and cancer biology, radiation physics, translational research, outcomes/health services research and comparative effectiveness research within radiation oncology.

12 Aug 2014

BioSpecifics Technologies total revenue for second quarter decreases by 19%

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX® in the EU, today announced its financial results for the second quarter ended June 30, 2014 and provided a corporate update.

12 Aug 2014

$Sacral magnetic stimulation effective in refractory stress incontinence$

Sacral magnetic stimulation effective in refractory stress incontinence

Sacral magnetic stimulation may be an effective treatment for stress urinary incontinence in women whose symptoms are refractory to standard therapies, a clinical trial suggests.

11 Aug 2014

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2014. Total revenue was $3.8 million and $6.2 million for the three and six months ended June 30, 2014, compared to $786,000 and $2.2 million for the same periods in 2013.

11 Aug 2014

ResMed releases new forward-thinking connected care solution for SDB treatment

ResMed today announced Air Solutions, a new forward-thinking connected care solution for treating sleep-disordered breathing that can benefit all stakeholders in the care continuum. The ResMed Air Solutions platform has data-driven components that span from diagnosis to treatment, compliance management and patient engagement.

From ResMed Corp 11 Aug 2014

BioSpecifics Technologies initiates CCH Phase 2 clinical trial in patients with lipoma

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX in the EU, announced today that it has injected the first patient in its placebo-controlled Phase 2 clinical trial of CCH for the treatment of lipoma.

8 Aug 2014

Patients recovering from total joint replacement surgery who receive AAT require less pain drugs

Patients recovering from total joint replacement surgery who receive animal-assisted therapy (AAT) require less pain medication than those who do not experience this type of therapy.

8 Aug 2014

Web-based psychological self-help may aid bipolar patients

A web-based self-management programme appears to be feasible and may be effective as an intervention for people with bipolar disorder.

7 Aug 2014

RSAM, Rettsyndrome.org renew commitment to defeat Rett syndrome

Rett Syndrome Association of Massachusetts and Rettsyndrome.org are thrilled to announce today their renewed commitment to work together to defeat Rett syndrome. A generous $150,000 donation from RSAM will support a Rettsyndrome.org approved grant to Dr. Michela Fagiolini's project at the Boston Children's Hospital: "Assessing NMDA receptor (NMDAr) modulators to ameliorate cortical regression in Rett syndrome".

7 Aug 2014

Blood cancer patients in the UK can now benefit from Roche's MabThera SC

Patients with one of the most common forms of blood cancer can now benefit from a new injection. MabThera subcutaneous (SC), which is given to patients just beneath the skin, can be administered in approximately five minutes, compared to the current two and a half hour intravenous (IV) infusion.

6 Aug 2014

Researcher examines effectiveness of brief interventions for reducing problem drug use

Peter Roy-Byrne, M.D., formerly of the University of Washington, Seattle, and colleagues write that few data exist on the effectiveness of brief (1-2 sessions) interventions for reducing problem drug use, a common issue in disadvantaged populations seeking care in safety-net medical settings (hospitals and community health clinics serving low-income patients with limited or no insurance).

6 Aug 2014

9.3% of U.S. cancer survivors are current smokers, shows study

Nine years after diagnosis, 9.3 percent of U.S. cancer survivors were current smokers and 83 percent of these individuals were daily smokers who averaged 14.7 cigarettes per day, according to a report in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research (AACR).

6 Aug 2014

FDA grants orphan-drug designation to Genoa's pirfenidone for treatment of IPF disease

Genoa Pharmaceuticals, the leader in inhaled medicines for pulmonary fibrosis, today announced the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to Genoa for the use of pirfenidone in their lead program - inhaled GP-101 for the treatment of IPF.

5 Aug 2014

Repurposed drug used to treat ovarian cancer gives positive results

A repurposed drug originally used to treat ovarian cancer saw positive results for patients with advanced peritoneal cancers during a phase I clinical trial at The University of Kansas Cancer Center.

5 Aug 2014

Neuralstem doses final patient with NSI-566 stem cells in Phase II trial

Neuralstem, Inc. announced that the final patient was treated in its Phase II trial using NSI-566 spinal cord-derived neural stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).

4 Aug 2014

Study shows sustained immunogenicity, efficacy and safety of GlaxoSmithKline's HPV vaccine

A long-term follow-up study (HPV-023; NCT00518336) shows the sustained efficacy, immunogenicity and safety of GlaxoSmithKline's human papilloma virus (HPV) vaccine Cervarix.

1 Aug 2014

Researchers one step closer to finding treatment for dengue fever

There have been several news reports that the world's first dengue vaccine will be available next year. However, the latest clinical trials show that the vaccine only provides a protection of around 50 per cent for DENV-2 and DENV-1, which are commonly found in Singapore.

1 Aug 2014